1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

Neurostimulation Devices Market, 2012 - 2017

  • May 2013
  • 123 pages
  • Roots Analysis Private Ltd.
Report ID: 1364217

Summary

Table of Contents

Search Inside

Neurostimulation devices are gaining acceptance as therapy alternative for certain chronic conditions such as pain. These devices have also found use in management of movement disorders including Parkinson’s disease and epilepsy. The currently available neurostimulators mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS).

The market is still niche, with limited number of devices available in the market. The 2012-2017 period will see the launch of several new devices, targeting new nerves of the nervous system and intending to manage new indications. Currently most of the available neurostimulation devices require surgical implantation as well as replacement surgeries after every few years. A number of companies are now focusing on the development of non-invasive transcutaneous or transdermal neurostimulation devices, which will drive the progressive growth in the market.

However, there are challenges to market entry for smaller companies, particularly due to market domination by few large medical device developers. This market model, however, did not deter the US based company Cyberonics from making its own niche in the VNS market, where it currently is the market leader. Smaller medical device companies with innovative technology have huge potential for growth in this yet unexplored market. Amongst other things, this report provides a detailed overview of the most promising pipeline technology and devices.

Scope of the Report
The Neurostimulation Devices Market report extensively examines various segments of the neurostimulation devices. In this report, we have identified the features of various devices, their benefits over conventional drug therapy while understanding the epidemiology of associated neurological diseases. The report focuses on analysing the existing market size and potential future growth of these devices across different segments and regions. We have also discussed the performance of leading players in the industry and the likely future developments driven by these companies.

The report highlights both the regional and global trends of the neurostimulation devices in the following key segments:
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Vagus Nerve Stimulation (VNS)
- Sacral Nerve Stimulation (SNS)

A key objective of the report is to enumerate existing commercial neurostimulation devices, pipeline devices and the market potential of these devices across different geographical regions. The report discusses various historical / likely future trends which have emerged / likely to emerge in the US, European and Rest of the world (RoW) markets including Japan and China. The research, analysis and insights presented in this report include the sales of neurostimulation devices present in the above key segments only. It also provides an overview of developments in the market related to the awareness, benefits and acceptance of these devices.

The market forecasts across different segments, regions, companies have been presented till 2017. 2011 is the base year and actual figures have been taken, analysed from publicly available information. Unless otherwise specified, all figures are presented in USD.

While the leading commercial devices, companies and segments have been considered thoroughly, the report also provides details on the pipeline devices in various stages of clinical trials. In addition, it highlights information on the regulatory approvals (e.g. FDA and CE mark) for these devices in the US, Europe and other markets.

Key Highlights
1. The global neurostimulation devices market is likely to achieve sales of USD 6,533 MM by 2017, growing at a compounded annual growth rate (CAGR) of 17.9% from 2011 to 2017.
2. Spinal Cord Stimulation (SCS) accounted for 50.5% of the sales of the currently marketed neurostimulation devices in 2011. This segment will continue to be the largest segment in the neurostimulation devices market over the forecast period (2012 to 2017).
3. Deep Brain Stimulation (DBS) segment will be the fastest growing segment during the forecast period (2012-2017), primarily driven by expansion of indications targeted by this class of devices and unavailability of effective drugs for many of the targeted indications.
4. The overall market is dominated by four leading companies - Medtronic, St. Jude Medical, Boston Scientific and Cyberonics. Together these companies accounted for about 90% of the total market in 2011.
5. The US was the largest market for neurostimulation devices in 2011 and accounted for 81.9% of the total market in 2011.
6. The US was also the largest market for DBS devices, accounting more than 70% of the sales in 2011.
7. The high cost of therapy is a deterrent to market acceptance and gaining reimbursement for the devices will be an important milestone for the device developers.
8. A number of companies are developing non-invasive neurostimulation devices, which will help increase the adoption of these devices as treatment alternative.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • April 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Myasthenia Gravis in 26 Major Markets Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases ...

Epiomic Epidemiology Series: Bell’s Palsy Forecast in 15 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bell’s palsy in 15 Major Markets Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.